TuHURA Biosciences, Inc./NV 8-K

What Happened

• TuHURA Biosciences filed an 8-K on April 8, 2026 disclosing two material items. On April 2, 2026 the Compensation Committee approved 2025 annual performance bonuses and a 5% cost-of-living salary increase for the company’s top executives: Dr. James Bianco (President & CEO) and Dan Dearborn (CFO). Separately, the company provided unaudited pro forma condensed combined statement of operations for the year ended December 31, 2025 reflecting the June 30, 2025 acquisition of Kineta, Inc. (the mergers were governed by a Merger Agreement dated December 11, 2024, as amended May 5, 2025).

Key Details

• CEO bonus approved: $490,536; new annual base salary: $605,956 (after 5% increase).
• CFO bonus approved: $163,393; new annual base salary: $403,676 (after 5% increase).
• Kineta acquisition closed June 30, 2025 (two-step merger structure); TuHURA filed an unaudited pro forma condensed combined statement of operations for year ended Dec 31, 2025 as if the mergers occurred on Jan 1, 2025.
• Pro forma financials are included as Exhibit 99.1 to the 8-K; they are unaudited and presented for illustrative purposes.

Why It Matters

• Executive compensation changes are cash and payroll items that affect operating expenses and cash burn; the disclosed bonuses and salary increases are concrete near-term impacts on G&A spending.
• The unaudited pro forma statement helps investors see what 2025 results might have looked like on a combined basis with Kineta, which can aid in evaluating revenue, expenses and comparability going forward. Note these pro forma figures are illustrative, unaudited, and subject to the usual forward‑looking cautions included in the filing.